Conclusion
In this study, we have demonstrated that testing forBRAFV600E can dictate the optimal strategy for
patients without preset preference. These patients pose the greatest
challenge to physicians in the decision-making prosses, hence additional
evidence-based tools possess great added value. In light of our finding,
performing a real-life study, with its costs and risks, is now better
justified and encouraged.